AstraZeneca has pushed back the anticipated high-level data readout for its PACIFIC-9 Phase 3 trial by six months, from H2 2026 to H1 2027. This delay, attributed to the event-driven nature of the study, could impact investor sentiment regarding the timeline for potential new treatments in non-small cell lung cancer.
AstraZeneca announced a delay in the high-level data readout for its PACIFIC-9 Phase 3 trial, moving it from the second half of 2026 to the first half of 2027. This trial is evaluating durvalumab in combination with monalizumab or oleclumab for non-small cell lung cancer. The delay, while attributed to the 'event-driven nature' of the study, means a longer wait for potential new treatment options and revenue streams for AstraZeneca. For traders, this could lead to short-term negative sentiment due to the extended timeline for a potentially significant drug, although the long-term implications depend on the eventual trial results. The key risk is that the delay might signal unforeseen challenges or simply a slower-than-expected progression of patient events, impacting future revenue projections.